ARCHITECT HBsAg Next Confirmatory Assay - Hepatitis B virus surface antigen IVD, kit, chemiluminescent immunoassay

Nazione: Australia

Lingua: inglese

Fonte: Department of Health (Therapeutic Goods Administration)

Commercializzato da:

Abbott Australasia Pty Ltd Diagnostic Division

Classe:

Class 4

Prodotto da:

Abbott Ireland Diagnostics Division Finisklin Business Park, SLIGO Ireland

Area terapeutica:

48321 - Hepatitis B virus surface antigen IVD, kit, chemiluminescent immunoassay

Indicazioni terapeutiche:

This assay consists of two single tests (HBsAgNx C1, also referred to as C1 and HBsAgNx C2, also referred to as C2) that are both one-step pre-treatment immunoassays for the confirmation of the presence of hepatitis B surface antigen (HBsAg) in human serum and plasma using chemiluminescent microparticle immunoassays (CMIA) technology with flexible assay protocols, referred to as Chemiflex. The HBsAg Next Confirmatory assay is a chemiluminescent microparticle immunoassay (CMIA) for the confirmation of the presence of hepatitis B surface antigen (HBsAg) in human serum and plasma including specimens collected post mortem (nonheart- beating) up to 24 hours after death by means of specific antibody neutralization on the ARCHITECT iSystem. It is intended to be used for the confirmation of samples found to be repeatedly reactive by HBsAg Next Qualitative.

Stato dell'autorizzazione:

A

Data dell'autorizzazione:

2020-05-18